Manish Saxena

Charterhouse Square
Charterhouse, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.

Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.

Journal: Journal of the American College of Cardiology

Published: February 13, 2026

New pharmacological therapies for hypertension.

New pharmacological therapies for hypertension.

Journal: Current opinion in nephrology and hypertension

Published: January 28, 2026

Lorundrostat for Uncontrolled Hypertension and Treatment-Resistant Hypertension-Reply.

Lorundrostat for Uncontrolled Hypertension and Treatment-Resistant Hypertension-Reply.

Journal: JAMA

Published: October 22, 2025

Zilebesiran Add-On Treatment for Inadequately Controlled Hypertension-Reply.

Zilebesiran Add-On Treatment for Inadequately Controlled Hypertension-Reply.

Journal: JAMA

Published: September 24, 2025

Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity and inflammatory biomarkers in pre-diabetes: a pilot placebo-controlled randomised clinical trial - CORRIGENDUM.

Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity and inflammatory biomarkers in pre-diabetes: a pilot placebo-controlled randomised clinical trial - CORRIGENDUM.

Journal: The British journal of nutrition

Published: July 31, 2025

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial.

Journal: JAMA

Published: June 30, 2025

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.

Journal: JAMA

Published: May 28, 2025

Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry.

Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry.

Journal: European journal of heart failure

Published: February 12, 2025

Effectiveness of Calorie Restriction for Weight Loss in Type 2 Diabetes Mellitus: A Systematic Review.

Effectiveness of Calorie Restriction for Weight Loss in Type 2 Diabetes Mellitus: A Systematic Review.

Journal: Cureus

Published: February 01, 2025

Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program.

Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: June 17, 2024

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.

36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension

Published: June 10, 2024

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry.

Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry.

Journal: Journal of cardiac failure

Published: June 05, 2024

Showing 1-12 of 57

Last Updated: 09/26/2026